Brief Psychotic Disorder

Back

Practice Essentials

Brief psychotic disorder is currently classified with schizophrenia spectrum and other psychotic disorders. It is differentiated from other related disorders by its sudden onset, its relatively short duration (< 1 month), and the full return of functioning.

Sudden onset is defined as change from non-psychotic state to a clearly psychotic state within 2 weeks, usually without prodrome.

Signs and symptoms

Brief psychotic disorder is characterized by the abrupt onset of 1 or more of the following symptoms:

Associated symptoms may include the following:

The following are also commonly observed in brief psychotic disorder:

A psychiatric history may be helpful.

Symptoms of brief psychotic disorder must be distinguished from culturally sanctioned response patterns that may resemble such symptoms. Cultural and religious background must always be taken into account when a judgment is to be made about whether a given patient’s beliefs are delusional.

Routine physical examination is necessary to exclude medical causes of psychosis. A careful Mental Status Examination is vital.

See Presentation for more detail.

Diagnosis

Specific laboratory studies for brief psychotic disorder do not exist. The history, the physical examination, and laboratory tests can help differentiate this condition from psychotic disorder secondary to general medical condition, delirium, and various other disorders.

No imaging studies are required for diagnosis; though CT, MRI, and EEG may be considered for assessing possible medical causes of psychosis.

See Workup for more detail.

Management

Management considerations include the following:

Treatment is brief and focused on being as nonrestrictive as possible

It is clinically imperative to prevent patients from harming themselves or others; thus, brief hospitalization may be necessary, potentially including brief seclusion or restraint for aggressive or combative patients

If symptoms are only minimally impairing the patient’s function and a specific stressor is identified, removing the stressor should suffice for treatment

If symptoms are disabling, an antipsychotic agent should be given, but for no longer than 1 month. Some of the commonly used antipsychotics include the following:

Once the acute attack has ended, further inpatient care is unnecessary. Individual, family, and group psychotherapy may be considered to help cope with stressors, resolve conflict, and improve self-esteem and self-confidence.

See Treatment and Medication for more detail.

Background

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), classifies brief psychotic disorder as belonging to the category of schizophrenia spectrum and other psychotic disorders.[1] These disorders are characterized by delusions, hallucinations, disorganized thinking, motor behavior abnormalities (including catatonia), and negative symptoms.

Brief psychotic disorder is distinguished from related disorders by the combination of sudden onset, relatively short duration (< 1 month) and full return of functioning. The diagnosis has been better appreciated and more completely studied in Scandinavia and other Western European countries than it has been in the United States.

Diagnostic criteria (DSM-5)

The specific DSM-5 criteria for brief psychotic disorder are as follows[1] :

In addition, the following must be specified:

Use additional code 293.89 (F06.1) when catatonia is associated with brief psychotic disorder to indicate the presence of the comorbid catatonia.

The severity of brief psychotic disorder can be specified on the basis of quantitative assessment of the primary symptoms (see above), though a diagnosis can be made without specifying severity in this manner. Each symptom is rated with respect to current severity on a 5-point scale that ranges from 0 (not present) to 4 (present and severe).

Pathophysiology and Etiology

The causes of brief psychotic episodes are largely unknown. Patients with personality disorder may have biologic or psychological vulnerability toward the development of psychotic symptoms. One or more severe stress factors, such as traumatic events, family conflict, employment problems, accidents, severe illness, death of a loved one, and uncertain immigration status, can precipitate brief reactive psychosis.

Psychodynamic theories suggest that the psychotic symptoms occur because of inadequate coping mechanisms, as a defense against prohibited fantasy, or as an escape from a specific psychological situation or an overwhelming stressful circumstance. It must be understood that the individual perceives the stress as totally overwhelming. Neither biologic nor psychological theories have been validated by carefully controlled clinical studies.

Some studies support a genetic vulnerability to brief psychotic disorder. Some data suggest an increased incidence of mood disorders in families of patients with brief psychotic disorder.

Epidemiology

United States statistics

Brief psychotic disorder is not common. In a follow-up study of 221 first-admission patients with affective and nonaffective psychoses, only 20 (9%) of the 221 experienced brief psychoses, and only 7 (3%) experienced acute brief psychoses.[4]

International statistics

According to an international epidemiologic study, the incidence of nonaffective acute remitting psychoses in contrast to that of schizophrenia, was 10-fold higher in developing countries than in industrialized countries.[5] Some clinicians believe that the disorder may occur most frequently in patients from lower socioeconomic classes, patients with preexisting personality disorders, and immigrants.

In nonindustrialized countries, such terms as yak, latah, koro, amok, and whitiligo have been used to describe psychotic states precipitated by stressful events. These and several similar cultural terms are now considered to be culture-bound syndromes.

Age- and sex-related demographics

Although this disorder may appear in adolescence or early adulthood it can occur accross the life span. The disorder is more common in patients late in the third to early in the fourth decade of life. Cases have also been recognized later in life. An international epidemiologic study found the incidence of the disorder to 2-fold higher in women than in men.[5] Study reports from the United States indicate an even preponderance in women.

Prognosis

Generally, brief psychotic disorder has a good prognosis and runs its course in less than 1 month. A good prognosis is usually associated with sudden onset, short duration of symptoms, and good premorbid adjustment; the prognosis is especially favorable for patients with no premorbid psychiatric history. According to European studies, 50-80% of all patients have no further major psychiatric problems.

As with any other psychotic episode, the risk of harm to self or others increases with an acute episode of brief psychotic disorder.[6] Some data indicate that a brief psychotic episode with an acute onset may be an early manifestation of severe mental disorder (eg, an affective disorder).[7] Patients may be at risk for committing suicide during psychotic episodes, especially when brief psychotic disorder is associated with affective symptoms.

Patient Education

Both the patient and the family must be educated about the illness and the potential adverse effects of the medications. Helpful Web sites include the following:

History

Brief psychotic disorder is characterized by the abrupt onset of 1 or more of the following symptoms:

Patients may present with a variety of associated symptoms, including the following:

The following are also commonly observed in brief psychotic disorder:

A psychiatric history may be helpful. Some clinicians believe that persons with personality disorders (eg, narcissistic, paranoid, borderline, schizotypal) are more prone to develop brief psychotic disorder in stressful situations.[8]

DSM-5 stresses that symptoms of brief psychotic disorder must be distinguished from culturally sanctioned response patterns that may resemble such symptoms.[1] For instance, hearing voices may be a component of some religious ceremonies; this generally would not be considered abnormal by most members of the religious community, and the voices typically would not persist into daily life. Cultural and religious background must always be taken into account when a judgment is to be made about whether a given patient’s beliefs are delusional.

Physical Examination

Routine physical examination is necessary to exclude medical causes of psychosis. A careful Mental Status Examination is vital. Patients usually present with severe psychotic agitation that may be associated with the following:

Psychological stressors in individuals with personality disorders may precipitate brief periods of psychotic symptoms. In such cases, if symptoms persist longer than 1 day, an additional diagnosis of brief psychotic disorder may be considered.

Approach Considerations

Specific laboratory studies for brief psychotic disorder do not exist. Comprehensive neuropsychiatric assessment, physical examination, and laboratory tests can help differentiate brief psychotic disorder from psychotic disorder secondary to general medical condition, delirium, and various other disorders. Routine and specific laboratory work may be needed to exclude other causes of psychoses.

Substance-induced psychotic disorder, substance-induced delirium, and substance intoxication can be distinguished from brief psychotic disorder by considering onset, course, urine drug screening, and blood alcohol levels.

No imaging studies are required to diagnose brief psychotic disorder. Further testing with modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and electroencephalography (EEG) may be considered, but such studies are useful only for diagnosing possible medical causes of the psychosis.

It is important to evaluate weight, metabolic state, cardiac, sexual and neurologic functions along with hematologic health as well as periodic monitoring for changes in these areas during the treatment is recomended.[9]

Approach Considerations

Because of the short duration of brief psychotic disorder, treatment is brief and focused on being as nonrestrictive as possible. However, it remains clinically imperative to prevent patients from harming themselves or others. Accordingly, patients experiencing an acute psychotic attack may have to be hospitalized briefly so that they can be evaluated and their safety ensured. If a patient becomes aggressive and combative, brief seclusion or restraint may be necessary.

If symptoms are only minimally impairing the patient’s function and a specific stressor is identified, removing the stressor should suffice for treatment of the brief psychotic episode.

If, however, symptoms are disabling, an antipsychotic agent should be given, but for no longer than 1 month. Commonly used typical (first-generation) antipsychotics include the following:

If adverse effects are intolerable, it may be helpful to use one of the atypical (second-generation) antipsychotics, for example:

At present, the available evidence is not sufficient to support the use of atypical antipsychotics to treat brief psychotic disorder. A case series suggests that rapid tranquilization with olanzapine can achieve symptom relief in acute psychosis.[10] A study involving intramuscular (IM) ziprasidone showed this agent to be more effective and better tolerated than IM haloperidol for treating acute psychosis.[11] In the authors’ experience, IM ziprasidone is the most effective treatment for acute severe psychotic agitation.

Once the acute attack has ended, further inpatient care is unnecessary. Individual, family, and group psychotherapy may be considered to help cope with stressors, resolve conflict, and improve self-esteem and self-confidence.

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications. Both typical and atypical antipsychotic agents have been used in the treatment of brief psychotic disorder.

Haloperidol (Haldol)

Clinical Context:  Haloperidol controls psychosis and provides rapid tranquilization. It can be administered with a benzodiazepine to protect against a lowered seizure threshold. IV haloperidol can be used effectively to treat acute psychotic agitation in a low dosage of 1-2 mg every 8 hours for 2-3 days, and the drug can be continued orally for the next several days until symptoms completely subside. In cases where it is difficulty to differentiate brief psychotic disorder and delirium, it should be kept in mind that IV haloperidol is also effective for delirium.

Thiothixene

Clinical Context:  Thiothixene blocks postsynaptic blockade of central nervous system (CNS) dopamine receptors, inhibiting dopamine-mediated effects. It provides rapid tranquilization in both oral and IM forms.

Risperidone (Risperdal)

Clinical Context:  Unlike haloperidol, risperidone has serotonergic blocking effects that alleviate negative symptoms of psychosis (eg, anhedonia, avolition, amotivation, and flat affect). It is well tolerated and has fewer extrapyramidal adverse effects than typical antipsychotics do. Dosages higher than 6 mg/day increase the risk of extrapyramidal effects.

Olanzapine (Zyprexa)

Clinical Context:  Olanzapine may inhibit serotonin, muscarinic, and dopamine effects. Its efficacy is similar to that of risperidone; it has fewer dose-dependent adverse effects but is more likely to be associated with weight gain.

Quetiapine (Seroquel)

Clinical Context:  Quetiapine may act by antagonizing dopamine and serotonin effects. Its efficacy is similar to those of risperidone and olanzapine; it has fewer dose-dependent adverse effects and poses less of a concern with regard to weight gain.

Paliperidone (Invega)

Clinical Context:  Paliperidone is the major active metabolite of risperidone and the first oral agent that can be given once daily. It is indicated for treatment of acute schizophrenia. The mechanism of action is not completely understood but is thought to involve mediation of central receptor antagonism of dopamine type 2 (D2) and serotonin type 2 (5-HT2A). It also elicits antagonist activity at alpha1- and alpha2-adrenergic receptors and histamine-1 receptors. It has no affinity for cholinergic, muscarinic, or beta-adrenergic receptors.

Class Summary

Antipsychotics are high-potency agents that provide rapid, predictable, and effective sedation in the management of patients who are acutely psychotic. They are less sedating and more easily titrated than lower-potency agents but more likely to cause extrapyramidal syndrome (EPS). They are often combined in the same syringe with a benzodiazepine to improve sedation and anxiety and reduce dystonia or akathisia. For prophylaxis of EPS, temporary use of a serotonin-dopamine antagonist may be needed.

Antipsychotics may be administered intramuscularly (IM) or intravenously (IV). In a nonemergency setting, haloperidol may be given orally. Haloperidol also has a monthly depot form (haloperidol decanoate), but this is not useful for brief psychotic disorder, because of the short duration of the psychotic episode.

Author

Mohammed A Memon, MD, Psychiatrist/Geriatric Psychiatrist, Carolina Center for Behavioral Health; Assistant Professor of Psychiatry, Virginia Commonwealth University School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

David Bienenfeld, MD, Professor, Departments of Psychiatry and Geriatric Medicine, Wright State University, Boonshoft School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Harold H Harsch, MD Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry and Department of Medicine, Froedtert Hospital, Medical College of Wisconsin

Harold H Harsch, MD is a member of the following medical societies: American Psychiatric Association

Disclosure: lilly Honoraria Speaking and teaching; Forest Labs None None; Pfizer Grant/research funds Speaking and teaching; Northstar None None; Novartis Grant/research funds research; Pfizer Honoraria Speaking and teaching; Sunovion Speaking and teaching; Otsuke Grant/research funds reseach; GlaxoSmithKline Grant/research funds research; Merck Honoraria Speaking and teaching

Michael F Larson, DO Clinical Instructor, Department of Child and Adolescent Psychiatry, Harvard Medical School; Psychiatrist, Harvard Vanguard Medical Associates and Private Practice

Michael F Larson, DO is a member of the following medical societies: American Academy of Addiction Psychiatry, American Academy of Child and Adolescent Psychiatry, and American Society of Addiction Medicine

Disclosure: Nothing to disclose.

Alan D Schmetzer, MD Professor Emeritus, Interim Chairman, Vice-Chair for Education, Associate Residency Training Director in General Psychiatry, Fellowship Training Director in Addiction Psychiatry, Department of Psychiatry, Indiana University School of Medicine; Addiction Psychiatrist, Midtown Mental Health Cener at Wishard Health Services

Alan D Schmetzer, MD is a member of the following medical societies: American Academy of Addiction Psychiatry, American Academy of Clinical Psychiatrists, American Academy of Psychiatry and the Law, American College of Physician Executives, American Medical Association, American Neuropsychiatric Association, American Psychiatric Association, and Association for Convulsive Therapy

Disclosure: Eli Lilly & Co. Grant/research funds Other

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013.
  2. Chaudron LH, Pies RW. The relationship between postpartum psychosis and bipolar disorder: a review. J Clin Psychiatry. 2003 Nov. 64(11):1284-92. [View Abstract]
  3. Valdimarsdottir U, Hultman CM, Harlow B, Cnattingius S, Sparen P. Psychotic illness in first-time mothers with no previous psychiatric hospitalizations: a population-based study. PLoS Med. 2009 Feb 10. 6(2):e13. [View Abstract]
  4. Susser E, Fennig S, Jandorf L, Amador X, Bromet E. Epidemiology, diagnosis, and course of brief psychoses. Am J Psychiatry. 1995 Dec. 152(12):1743-8. [View Abstract]
  5. Susser E, Wanderling J. Epidemiology of nonaffective acute remitting psychosis vs schizophrenia. Sex and sociocultural setting. Arch Gen Psychiatry. 1994 Apr. 51(4):294-301. [View Abstract]
  6. Jorgensen P, Mortensen PB. Reactive psychosis and mortality. Acta Psychiatr Scand. 1990 Mar. 81(3):277-9. [View Abstract]
  7. Correll CU, Smith CW, Auther AM, McLaughlin D, Shah M, Foley C, et al. Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. J Child Adolesc Psychopharmacol. 2008 Oct. 18(5):475-90. [View Abstract]
  8. Jorgensen P, Bennedsen B, Christensen J, Hyllested A. Acute and transient psychotic disorder: comorbidity with personality disorder. Acta Psychiatr Scand. 1996 Dec. 94(6):460-4. [View Abstract]
  9. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guidelines for the treatment of patients with schizophrenia. Arlington American Psychiatric Association. 2004. [View Abstract]
  10. Karagianis JL, Dawe IC, Thakur A, et al. Rapid tranquilization with olanzapine in acute psychosis: a case series. J Clin Psychiatry. 2001. 62 Suppl 2:12-6. [View Abstract]
  11. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry. 2000 Dec. 61(12):933-41. [View Abstract]